Navigation Links
Virus combination effective against deadly brain tumor, Moffitt Cancer Center study shows
Date:6/20/2013

A combination of the myxoma virus and the immune suppressant rapamycin can kill glioblastoma multiforme, the most common and deadliest malignant brain tumor, according to Moffitt Cancer Center research. Peter A. Forsyth, M.D., of Moffitt's Neuro-Oncology Program, says the combination has been shown to infect and kill both brain cancer stem cells and differentiated compartments of glioblastoma multiforme.

The finding means that barriers to treating the disease, such as resistance to the drug temozolomide, may be overcome. The study, by Forsyth and colleagues in Canada, Texas and Florida, appeared in a recent issue of Neuro-Oncology.

"Although temozolomide improves survival for patients with glioblastoma multiforme, drug resistance is a significant obstacle," said Forsyth, the study lead author. "Oncolytic viruses that infect and break down cancer cells offer promising possibilities for overcoming resistance to targeted therapies."

The authors note that oncolytic viruses have the potential to provoke a multipronged attack on a tumor, with the potential to kill cancer cells directly through viral infection and possibly through inducing the immune system to attack the tumor. The multipronged approach might get around some of the classical resistance mechanisms that have plagued both targeted therapies and conventional chemotherapies.

Several oncolytic viruses, both alone or in combination with small molecule inhibitors, have been tested and show promise for malignant gliomas. However, most have not been effective in killing cancer cells. Two likely obstacles may be the patient's own anti-viral immune response and limited virus distribution.

"Based on our previous work with myxoma virus, we considered it to be an excellent oncolytic virus candidate against brain cancer stem cells," explained Forsyth.

The researchers found that brain cancer stem cells were susceptible to myxoma virus in the laboratory cultures (in vitro) and in animal models (in vivo), including in temozolomide-resistant cell lines.

"We also found that myxoma virus with rapamycin is a potentially useful combination. The idea that cancer cells can be killed by a harmless virus is an exciting prospect for therapy," Forsyth said.

The precise mechanism rapamycin uses to enhance infection in brain cancer stem cells is unknown, and the combination therapy does not result in cures. However, researchers are investigating other drugs that may improve the effectiveness of myxoma virus when used in combination, and they are evaluating the use of other strains of myxoma virus that might be more effective.

"Although our study adds myxoma virus to the list of oncolytic viruses capable of infecting and killing these cells, which strengthens its candidacy for clinical application, our model will need clinical application to determine its safety for patients," concluded the authors. "We expect that intracranial injections of myxoma virus will be safe based on our extensive preclinical work and the demonstrated safety of other oncolytic viruses in clinical trials."


'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Mayo Clinic: Rotavirus vaccine given to newborns in Africa is effective
2. The Fight Against West Nile Virus Begins Again: Learn Simple, Effective Tips to Protect Yourself and Family
3. Rihanna Herpes and Lipstick Fiasco Shows Need for Effective Herpes Remedy; polyDNA Recommends Gene-Eden-VIR to Kill Latent Herpes Virus
4. National Congenital Cytomegalovirus Awareness Month
5. Cytomegalovirus might speed brain-cancer growth
6. Modified Polio Virus May Help Fight Brain Tumors, Study Suggests
7. Ferrets, pigs susceptible to H7N9 avian influenza virus
8. Effective virus protection without anti-virus software, identifies idcloak
9. Poliovirus vaccine trial shows early promise for recurrent glioblastoma
10. H1N1 Flu Virus Detected in Seals Off California Coast
11. Unusual Heat May Have Boosted West Nile Virus Last Year: CDC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... , ... Alert Sentry Group LLC., a leader in the Personal Emergency Response ... and the iSAFE Plus. These iSAFE products are the most affordable and most advanced ... iSAFE Plus offer direct GPS Location and two-way calling with the push of a ...
(Date:3/28/2017)... Greifensee, Switzerland (PRWEB) , ... March 28, 2017 ... ... testing for laboratory instruments are critical to ensuring high-quality results and maintaining GMP ... and Qualification of Laboratory Instruments in accordance with GMP requirements " these requirements ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... measurement of corrosive ions found in power plant water and steam. , Chlorides ... as turbines and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... will be offered by the American Association of Integrative Medicine and available for ... healthcare providers at the AutismOne 2017 Conference in Colorado Springs. , Ed Arranga, ...
(Date:3/28/2017)... ... , ... Silicon Valley Hair Institute, the San Francisco Bay Area leader in ... hair loss. Although hair transplant procedures can be seen as more of a man’s ... be two reasons a woman may see her hair thinning. , “We are used ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... United Kingdom and  BOSTON , March 28, ... Linguamatics today announced a partnership with ... The agreement allows pharmaceutical companies to extract key ... I2E text mining technology. The ... of the top 20 global pharmaceutical companies. The ...
(Date:3/28/2017)... March 28, 2017  CASI Pharmaceuticals, Inc. (Nasdaq: ... addressing cancer and other unmet medical needs, announced ... for Cancer Research annual meeting.  The first poster ... "Evaluation of ENMD-2076 in Combination with Anti-PD1 ... poster to be presented on April 4 is ...
(Date:3/28/2017)... CAMBRIDGE, England , March 28, 2017 ... in collaborative research with Cambridge ... Milner Therapeutics Consortium   The Milner Therapeutics Institute ... Therapeutics Consortium. Elysium Health has committed significant investment for collaborative ... over the next four years. This is the first major ...
Breaking Medicine Technology: